Inflectra (infliximab-dyyb) — FDA-Approved Biosimilar to Remicade (infliximab)

TNF-alpha Inhibitor Biosimilar (IV) · Approved 2016 · $0–$35/mo for most insured patients

🔬 What Is Inflectra?

Inflectra (infliximab-dyyb) is an FDA-approved biosimilar to Remicade (infliximab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Inflectra (infliximab-dyyb) was the first FDA-approved Remicade biosimilar, approved in 2016. It is manufactured by Celltrion and distributed by Pfizer in the US. Given by IV infusion, it is approved for all Remicade indications with the same dosing schedule.

🛒 Order Inflectra — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Pfizer RxPathways

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Inflectra Overview

Property	Details
Brand Name	Inflectra
Generic Name	infliximab-dyyb
Reference Biologic	Remicade (infliximab)
Manufacturer	Pfizer/Celltrion
Drug Class	TNF-alpha Inhibitor Biosimilar (IV)
FDA Approval	2016
Route	IV infusion
Approved Conditions	Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis
Copay Program	Pfizer RxPathways — $0–$35/mo for most insured patients

Approved Conditions

✓Rheumatoid Arthritis✓Ankylosing Spondylitis✓Psoriatic Arthritis✓Plaque Psoriasis✓Crohn's Disease✓Ulcerative Colitis

Inflectra vs Remicade (infliximab)

Inflectra has been demonstrated to be biosimilar to Remicade (infliximab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Remicade (infliximab) should discuss any potential switch to Inflectra with their prescriber.

Factor	Inflectra	Remicade (infliximab)
FDA Status	Biosimilar (approved 2016)	Reference biologic
Active Ingredient	infliximab-dyyb	infliximab
Mechanism	TNF-alpha Inhibitor)	Same
Approved Indications	Same as Remicade (infliximab)	Multiple FDA-approved
Typical Patient Cost	$0–$35/mo for most insured patients	$0–$35/mo (varies by plan)

Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Inflectra underwent rigorous clinical studies demonstrating biosimilarity to Remicade (infliximab). Your prescriber can discuss whether Inflectra is appropriate for your specific situation.

Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Inflectra and ensure a seamless supply transition.

Most commercial insurance plans and Medicare Part D cover Inflectra with prior authorization. In many cases, Inflectra may have a lower tier placement on formularies than Remicade (infliximab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Pfizer RxPathways copay program to minimize your out-of-pocket costs.

Without insurance, Inflectra costs approximately $4900/month at list price — lower than Remicade (infliximab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Pfizer RxPathways. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗

FDA Biosimilar ApprovalsFDA

🔗

BiosimilarWikipedia

🔗

ACR Biosimilar PositionACR

🔗

Biosimilar DevelopmentNIH/NCBI

🔗

Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Inflectra requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.